GlassScriptPhysician profile
Michael W Joyce
NPI 1780644005
$7,109.13
in general payments reported to CMS, 2019-2025
26 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,718 · 2020: $1,536 · 2021: $1,130 · 2023: $289 · 2024: $62.94 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,551.32 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,168.85 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.32 | 2019-2021 | |
| Grifols USA, LLC | $617.88 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $450.40 | 2019-2021 | |
| Genentech USA, INC. | $442.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $292.90 | 2019-2021 | |
| Mylan Specialty L.P. | $256.00 | 2019-2021 | |
| Insmed, INC. | $181.45 | 2019-2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $180.65 | 2019 | |
| Genzyme Corporation | $171.77 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $169.73 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $132.49 | 2019-2020 | |
| Eisai INC. | $120.29 | 2021 | |
| Stryker Corporation | $112.39 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $93.29 | 2019 | |
| Philips North America LLC | $85.81 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $78.49 | 2019-2021 | |
| Exact Sciences Corporation | $68.15 | 2023-2025 | Cologuard Collection Kit |
| United Therapeutics Corporation | $37.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.75 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $30.22 | 2020-2021 | |
| Novo Nordisk INC | $29.49 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $23.83 | 2025 | Closurefast |
| Lilly USA, LLC | $15.97 | 2024 | Mounjaro |
| Shire North American Group INC | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.